𝔖 Bobbio Scriptorium
✦   LIBER   ✦

SUMMARY MEASURES AND STATISTICS FOR COMPARISON OF QUALITY OF LIFE IN A CLINICAL TRIAL OF CANCER THERAPY

✍ Scribed by DIANE L. FAIRCLOUGH


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
457 KB
Volume
16
Category
Article
ISSN
0277-6715

No coin nor oath required. For personal study only.

✦ Synopsis


Assessment of health related quality of life (QOL) has become an important endpoint in many clinical trials of cancer therapy. Most of these studies entail multiple QOL scales that are assessed repeatedly over time. As a result, the problem of multiple comparisons is a primary analytic challenge with these trials. The use of summary measures and statistics both reduces the number of hypotheses tested and facilitates the interpretation of trial results where the primary question is 'Does the overall QOL differ between treatment arms?' I present two classes of summary measures that are sensitive to consistent trends in the same direction across multiple assessment times or multiple QOL scales. Missing data strongly influences the choice between the two classes, where one class handles missing data on an individual basis, while the other class uses model-based strategies. I present the results from a clinical trial of adjuvant therapy for breast cancer that use summary measures with a focus on the practical issues that affect these analysis strategies, such as missing data and integration of QOL with efficacy endpoints such as survival.


πŸ“œ SIMILAR VOLUMES


Statistical analysis of quality of life
✍ Andrea B. Troxel; Diane L. Fairclough; Desmond Curran; Elizabeth A. Hahn πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 255 KB πŸ‘ 2 views

We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data mechanisms. A section on presentation of stud

Why are missing quality of life data a p
✍ Diane L. Fairclough; Harriet F. Peterson; Victor Chang πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 116 KB πŸ‘ 2 views

Assessment of health related quality of life has become an important endpoint in many cancer clinical trials. Because the participants of these trials often experience disease and treatment related morbidity and mortality, non-random missing assessments are inevitable. Examples are presented from se

Comparison of several model-based method
✍ Diane L. Fairclough; Harriet F. Peterson; David Cella; Phil Bonomi πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 250 KB πŸ‘ 1 views

This paper considers five methods of analysis of longitudinal assessment of health related quality of life (QOL) in two clinical trials of cancer therapy. The primary difference in the two trials is the proportion of participants who experience disease progression or death during the period of QOL a

Missing quality of life data in cancer c
✍ JΓΌrg Bernhard; David F. Cella; Alan S. Coates; Lesley Fallowfield; Patricia A. G πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 173 KB πŸ‘ 2 views

Measurement of quality of life (QOL) in cancer clinical trials has increased in recent years as more groups realize the importance of such endpoints. A key problem has been missing data. Some QOL data may unavoidably be missing, as for example when patients are too ill to complete forms. Other impor